Fig. 4.

Dasatinib inhibits αSMA and fibronectin expression in HFLFs through Src. A. Western blot images of HFLFs maintained in 2% serum (partial serum starvation) and treated with 10 nM dasatinib or 10 µM PP2 (low dose) or 40 nM dasatinib and 40 µM PP2 (high dose) for 24 h, and the lysates probed with antibodies against αSMA, fibrinectin, pY⁴¹⁶Src and total cSrc. B. Bar graphs of showing densitometry analysis of HFLF lysate Western blot images after treatment with 10 nM dasatinib or 10 µM PP2 (low dose) or 40 nM dasatinib and 40 µM PP2 (high dose) for 24 h showing expression changes in αSMA, fibronectin, pY⁴¹⁶Src and total cSrc. (n=3). Data presented as mean ± S.D. *P<0.05; #P<0.01; §P<0.001